Targeting IL-23 for the interception of obesity-associated colorectal cancer
Open Access
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
- NCI (R01CA213987)
- NIDDK (R01DK118427)
- US Department of Veterans Affairs
This publication has 48 references indexed in Scilit:
- Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growthNature, 2012
- Bacteroides uniformis CECT 7771 Ameliorates Metabolic and Immunological Dysfunction in Mice with High-Fat-Diet Induced ObesityPLOS ONE, 2012
- Chemoprevention of Colon and Small Intestinal Tumorigenesis in APCMin/+ Mice by Licofelone, a Novel Dual 5-LOX/COX Inhibitor: Potential Implications for Human Colon Cancer PreventionCancer Prevention Research, 2011
- Gut barrier dysfunction in the ApcMin/+ mouse model of colon cancer cachexiaBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2011
- Recent advances in understanding the role of diet and obesity in the development of colorectal cancerProceedings of the Nutrition Society, 2011
- Role of intestinalBifidobacterium pseudolongumin dietary fructo-oligosaccharide inhibition of 2,4-dinitrofluorobenzene-induced contact hypersensitivity in miceBritish Journal of Nutrition, 2009
- IL-23 promotes tumour incidence and growthNature, 2006
- Understanding the IL-23–IL-17 immune pathwayTrends in Immunology, 2006
- Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses.Journal of Clinical Investigation, 1996
- Circulating antiinflammatory cytokine IL-10 in patients with inflammatory bowel disease (IBD)Clinical and Experimental Immunology, 1995